Known safety concerns, contraindications, and risk factors.
Active cancer or history of hormone-sensitive malignancy
GH and IGF-1 promote cellular proliferation. Any active or hormone-responsive cancer is an absolute contraindication.
Pituitary tumours or hypothalamic disorders
Direct contraindication for GHRH secretagogue therapy. Stimulating an already compromised pituitary axis risks uncontrolled hormone output.
Uncontrolled diabetes or significant cardiovascular disease
GH elevation worsens insulin resistance and can increase cardiac workload. Stable metabolic baseline required before use.
Pregnancy, breastfeeding, or paediatric use
Insufficient safety data for developing fetuses, nursing infants, or children outside regulated deficiency settings. No human reproductive toxicity data exists.
Concurrent use of insulin or oral hypoglycaemics
GH counter-regulates insulin. Combined use may require dose adjustment of diabetes medications and creates unpredictable glucose swings.